DIA/Tufts CSDD Research: AI Saving Time in Drug Development

DIA and the Tufts Center for the Study of Drug Development (Tufts CSDD), in collaboration with 16 biopharmaceutical companies and CROs, conducted a study to map current use of and experience with artificial intelligence (AI) and machine learning (ML), and their ability to reduce time across activities, in the drug development lifecycle. “We benchmarked various applications of AI and ML to 36 activities within clinical operations and development. We focused on design and planning, execution, and regulatory submissions, and looked at time reductions from investments in the use of AI and ML in a typical development program,” explains Tufts CSDD Director of Sponsored Research Mary Jo Lamberti in this interview with Stephanie Rosner (Scientific Program Manager for AI, DIA). “We expect to see higher levels of full implementation across all activities over the next few years.”

You can listen to DIA/Tufts CSDD Research: AI Saving Time in Drug Development online on Radio and Podcast. Open the player on this page to stream the available audio.

DIA/Tufts CSDD Research: AI Saving Time in Drug Development is an episode from DIA: Driving Insights to Action.

This episode is 11:13 long.

This episode was published on Jan 17, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from DIA: Driving Insights to Action when more episodes are available from the podcast feed.